HighTower Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

HighTower Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,669	Closed	-$286K	–	3444
2021 Q1	$286K	Sell	1,669 -5	-0.3%	-$990	﹤0.01%	2339
2020 Q4	$362K	Buy	+1,674	New	+$362K	﹤0.01%	1815
2019 Q2	–	Sell	-3,550	Closed	-$260K	–	2542
2019 Q1	$260K	Buy	+3,550	New	+$241K	﹤0.01%	1801
2018 Q4	–	Sell	-4,250	Closed	-$200K	–	2402
2018 Q3	$200K	Hold	4,250	–	–	﹤0.01%	1961
2018 Q2	$209K	Buy	+4,250	New	+$161K	﹤0.01%	1874

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

HighTower Advisors's MRTX Position: Q2 2021 in Review

HighTower Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 1,669 shares — an estimated $286K sold.

HighTower Advisors first reported a position in MRTX in Q2 2018 and held it in 5 quarters. The position peaked at $362K in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

HighTower Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
HighTower Advisors sold 1,669 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $286K.
HighTower Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
HighTower Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $362K in Q4 2020.
245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on HighTower Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.